Triall announces the official release of the Triall whitepaper. This document outlines the foundation’s vision and plans for building towards the world’s first multisided clinical trial platform that is open to all clinical research professionals, utilizing an enterprise-grade blockchain infrastructure to enable a future of smarter, safer, and more efficient clinical trials.
Triall was initiated with the purpose to address several persistent industry pain points that make the conduct of clinical trial operations overly complex, lengthy, and resource-inefficient. Together with its main technology partner Sphereon, Triall has been developing a series of modular applications that directly tailor to these pain points, making use of the blockchain infrastructure of the Factom Protocol where it truly adds value.
“We’re thrilled to now be able to share our vision and plans, and we look forward to joining forces with more stakeholders in the clinical research and blockchain communities over the months to come.” – Hadil Es-Sbai, Triall Foundation
Hadil Es-Sbai, President and Executive Director of Triall: “The release of the Triall whitepaper marks an important milestone in a journey that we initiated over two years ago. It summarizes the results of an exciting process of collaborative research, design, and development efforts between our team of clinical innovation specialists and consortium partners.
We’re thrilled to now be able to share our vision and plans, and we look forward to joining forces with more stakeholders in the clinical research and blockchain communities over the months to come. Together we will be able to realize a truly inclusive ‘ecosystem’ for all clinical research professionals.”
Triall’s first deliverable, a blockchain-enabled document authenticator and data management application, will enable users to establish verifiable proof of the integrity and authenticity of clinical data and documents, and establish an immutable audit trail of their evolution over the course of the clinical trial. These functionalities promise to improve the reliability, auditability, and efficiency of clinical operations throughout the drug development chain, and fully answer to increasing calls for meticulous documentation as decreed by the FDA, EMA and other regulators. A functioning prototype of the application is now being enrolled in a first, real-world clinical trial.
You may download the whitepaper here.